Genmab Shares Outstanding 2019-2022 | GMAB
Genmab shares outstanding history from 2019 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Genmab shares outstanding for the quarter ending September 30, 2022 were 0.659B, a 0.24% decline year-over-year.
- Genmab 2021 shares outstanding were 0.66B, a 0.24% increase from 2020.
- Genmab 2020 shares outstanding were 0.659B, a 3.53% increase from 2019.
- Genmab 2019 shares outstanding were 0.636B, a 2.58% increase from 2018.
Genmab Annual Shares Outstanding (Millions of Shares) |
2021 |
660 |
2020 |
659 |
2019 |
636 |
2018 |
620 |
Genmab Quarterly Shares Outstanding (Millions of Shares) |
2022-09-30 |
659 |
2022-06-30 |
660 |
2022-03-31 |
660 |
2021-12-31 |
660 |
2021-09-30 |
661 |
2021-06-30 |
660 |
2021-03-31 |
660 |
2020-12-31 |
659 |
2020-09-30 |
659 |
2020-06-30 |
658 |
2020-03-31 |
658 |
2019-12-31 |
636 |
2019-09-30 |
649 |
2019-06-30 |
629 |
2019-03-31 |
62 |
2018-12-31 |
62 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$25.237B |
$1.349B |
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
|